Ebola vaccine found to offer immunity

A study led by the Oxford Vaccine Group at the University of Oxford has tested a new Ebola vaccine which has been found to provide immunity for up to a year after immunisation.

During the study, healthy volunteers were given one vaccine dose, developed by Janssen Vaccines & Prevention B.V. based on Janssen’s AdVac technology and MVA-BN technology from Bavarian Nordic A/S, to prime their immune system, and the alternative vaccine to boost their immune response.

Commenting on the findings, Dr Matthew Snape from the Department of Paediatrics at Oxford, who led the research, said: “The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive.

“The fact that all participants retained Ebola-specific antibodies to the end of the study does raise hope that this vaccine could induce responses that last for several years.

“This study was conducted in a European population, so it’s important to note that immune responses may differ in a sub-Saharan African population, but these vaccine candidates are currently being assessed in this region.

“Additional research is also needed to explore the persistence of immunity beyond the one year mark and the response to booster doses of vaccine.”

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho